Richard M. Stone

Richard M. Stone, MD is Chief of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, where he has led one of the most productive AML clinical research programs in the United States for more than three decades. He is most prominently known as the overall Principal Investigator of the phase III RATIFY trial (NEJM 2017), the definitive study demonstrating that midostaurin combined with standard 7+3 induction and consolidation chemotherapy significantly improved overall survival in FLT3-mutated AML (HR 0.78; 4-year OS 51.4% vs. 44.3%), leading to the first FDA approval of a kinase inhibitor in AML front-line therapy. Dr. Stone has been a central figure in the clinical development of all generations of FLT3 inhibitors, including early trials of sorafenib, midostaurin, and quizartinib, as well as the more selective gilteritinib. He has led or co-led major cooperative group trials through ECOG-ACRIN, ALLIANCE, and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), including studies of post-transplant maintenance in FLT3-AML. Dr. Stone is the former Chair of the ECOG Leukemia Committee and has authored over 400 peer-reviewed publications. He is a frequent invited speaker at ASH and ASCO and has trained many of the leading leukemia physicians practicing in the United States today.